| scholarly article | Q13442814 |
| P356 | DOI | 10.1172/JCI21716 |
| P8608 | Fatcat ID | release_tjsbyct4u5atbitdydjd7iem6q |
| P932 | PMC publication ID | 514587 |
| P698 | PubMed publication ID | 15343390 |
| P5875 | ResearchGate publication ID | 8370007 |
| P2093 | author name string | Rui Zhao | |
| Xuerong Wang | |||
| Giuseppina Nucifora | |||
| Yogen Saunthararajah | |||
| Donglan Li | |||
| Silvia Buonamici | |||
| Hongyu Ni | |||
| Larry Brace | |||
| Yiqing Chi | |||
| P2860 | cites work | Interaction of EVI1 with cAMP-responsive element-binding protein-binding protein (CBP) and p300/CBP-associated factor (P/CAF) results in reversible acetylation of EVI1 and in co-localization in nuclear speckles | Q24291719 |
| Structure and transcription of the human c-mpl gene (MPL) | Q24313041 | ||
| Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family | Q24314719 | ||
| Transcriptional regulation of erythropoiesis: an affair involving multiple partners | Q28200921 | ||
| The role of EVI1 in normal and leukemic cells | Q28206742 | ||
| EVI1 promotes cell proliferation by interacting with BRG1 and blocking the repression of BRG1 on E2F1 activity | Q28209175 | ||
| High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients | Q28209409 | ||
| Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines | Q28281211 | ||
| Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor | Q28288945 | ||
| Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly | Q33334800 | ||
| Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts | Q33357481 | ||
| Hematopoietic deficiencies in c-mpl and TPO knockout mice | Q33501697 | ||
| Myelodysplastic syndromes: recent advances | Q34428363 | ||
| New approaches to the treatment of myelodysplasia. | Q34605838 | ||
| Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome | Q35007250 | ||
| Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia | Q35035913 | ||
| Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. | Q35186892 | ||
| Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations | Q35210567 | ||
| Myelodysplastic syndrome | Q35591434 | ||
| The myelodysplastic syndromes: a matter of life or death | Q35596717 | ||
| Loss of erythropoietin responsiveness in erythroid progenitors due to expression of the Evi-1 myeloid-transforming gene | Q36413795 | ||
| Four of the seven zinc fingers of the Evi-1 myeloid-transforming gene are required for sequence-specific binding to GA(C/T)AAGA(T/C)AAGATAA. | Q36690799 | ||
| Expression of the Evi-1 zinc finger gene in 32Dc13 myeloid cells blocks granulocytic differentiation in response to granulocyte colony-stimulating factor | Q36808211 | ||
| Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML | Q37116614 | ||
| Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations | Q38305391 | ||
| The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells | Q40722488 | ||
| Versatile retroviral vectors for potential use in gene therapy | Q45867146 | ||
| Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state | Q57006319 | ||
| Chromosomal location of Evi-1, a common site of ecotropic viral integration in AKXD murine myeloid tumors | Q69918163 | ||
| Erythroid defects and increased retrovirally-induced tumor formation in Evi1 transgenic mice | Q73166088 | ||
| Forced expression of the leukemia-associated gene EVI1 in ES cells: a model for myeloid leukemia with 3q26 rearrangements | Q73170962 | ||
| Myelodysplastic syndromes | Q78556827 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | myelodysplastic syndrome | Q954625 |
| P304 | page(s) | 713-719 | |
| P577 | publication date | 2004-09-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | EVI1 induces myelodysplastic syndrome in mice. | |
| P478 | volume | 114 |
| Q38226741 | -7/7q- syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity |
| Q37270690 | A novel variant on chromosome 7q22.3 associated with mean platelet volume, counts, and function |
| Q39313400 | A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression |
| Q42218756 | Aberrant expression of ecotropic viral integration site-1 in acute myeloid leukemia and acute lymphoblastic leukemia |
| Q34043133 | Acetylation of the proto-oncogene EVI1 abrogates Bcl-xL promoter binding and induces apoptosis |
| Q35113804 | Activation of non-canonical TGF-β1 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis |
| Q33381924 | Allogeneic bone marrow transplantation and donor lymphocyte infusion in a mouse model of irradiation-induced myelodysplastic/myeloproliferation syndrome (MD/MPS): evidence for a graft-versus-MD/MPS effect |
| Q46956230 | Association of 3q21q26 syndrome and late-appearing Philadelphia chromosome in acute myeloid leukemia |
| Q41640013 | Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities |
| Q54608168 | Characterization of a recurrent translocation t(2;3)(p15-22;q26) occurring in acute myeloid leukaemia. |
| Q56965502 | Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities |
| Q33558709 | Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study |
| Q33552027 | Concise review: lessons learned from clinical trials of gene therapy in monogenic immunodeficiency diseases |
| Q34508425 | Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. |
| Q36747434 | Critical role of miR-9 in myelopoiesis and EVI1-induced leukemogenesis |
| Q82644974 | De novo acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): a clinicopathologic and cytogenetic study of an entity recently added to the WHO classification |
| Q38880958 | Deregulated microRNA expression and its pathogenetic implications for myelodysplastic syndromes |
| Q38089064 | Diagnostic challenges in the myelodysplastic syndromes: the current and future role of genetic and immunophenotypic studies |
| Q24530021 | Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms |
| Q35265855 | Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia |
| Q84583338 | EVI-1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization |
| Q93343887 | EVI-1 modulates arsenic trioxide induced apoptosis through JNK signalling pathway in leukemia cells |
| Q43486412 | EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia. |
| Q39207812 | EVI1 and MDS1/EVI1 expression during primary human hematopoietic progenitor cell differentiation into various myeloid lineages. |
| Q64147072 | EVI1 carboxy-terminal phosphorylation is ATM-mediated and sustains transcriptional modulation and self-renewal via enhanced CtBP1 association |
| Q36057626 | EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. |
| Q57471963 | EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcription |
| Q38299701 | EVI1 promotes tumor growth via transcriptional repression of MS4A3. |
| Q39957388 | EVI1 recruits the histone methyltransferase SUV39H1 for transcription repression |
| Q38001764 | Ecotropic viral integration site 1, stem cell self-renewal and leukemogenesis |
| Q38726265 | Ecotropic viral integration site I regulates alpha1, 6-fucosyl transferase expression and blocks erythropoiesis in chronic myeloid leukemia |
| Q50594569 | Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. |
| Q26828777 | Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they? |
| Q36698269 | Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy |
| Q37763616 | Evi-1 as a critical regulator of leukemic cells |
| Q42223517 | Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia |
| Q35669072 | Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity |
| Q52021980 | Evi1 is specifically expressed in the distal tubule and duct of the Xenopus pronephros and plays a role in its formation. |
| Q28263954 | Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration |
| Q36233848 | Gatekeeper pathways and cellular background in the pathogenesis and therapy of AML. |
| Q34473374 | Gene therapy of chronic granulomatous disease: the engraftment dilemma |
| Q34094502 | Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease |
| Q36453658 | Genotoxicity of retroviral integration in hematopoietic cells. |
| Q34796524 | Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia |
| Q24328884 | Haploinsufficiency of SAMD9L, an endosome fusion facilitator, causes myeloid malignancies in mice mimicking human diseases with monosomy 7 |
| Q33441057 | Hematopoietic transcription factor mutations: important players in inherited platelet defects. |
| Q39824884 | Inducible expression of EVI1 in human myeloid cells causes phenotypes consistent with its role in myelodysplastic syndromes |
| Q35847760 | Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells |
| Q39399124 | Intratumoral Heterogeneity of Frameshift Mutations in MECOM Gene is Frequent in Colorectal Cancers with High Microsatellite Instability |
| Q37089028 | Leukaemia cell of origin identified by chromatin landscape of bulk tumour cells. |
| Q81320653 | Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16 |
| Q36812700 | Leukemogenesis of the EVI1/MEL1 gene family |
| Q57920984 | MECOM-associated syndrome: a heterogeneous inherited bone marrow failure syndrome with amegakaryocytic thrombocytopenia |
| Q34006457 | Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome |
| Q37406090 | Molecular bases of myelodysplastic syndromes: lessons from animal models |
| Q37937809 | Molecular biology of myelodysplastic syndromes |
| Q37707390 | Molecular mechanisms involved in the progression of myelodysplastic syndrome |
| Q36445968 | Molecular pathophysiology of myelodysplastic syndromes. |
| Q37186801 | Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review |
| Q33767319 | Mouse models of myelodysplastic syndromes |
| Q40214885 | Multipotent adult progenitor cells improve the hematopoietic function in myelodysplasia. |
| Q28586559 | Mutation at the Evi1 locus in Junbo mice causes susceptibility to otitis media |
| Q35059425 | Myelodysplasia is in the niche: novel concepts and emerging therapies |
| Q35001132 | Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"? |
| Q38050694 | Myelodysplastic syndrome hematopoietic stem cell |
| Q37179077 | Myelodysplastic syndromes: molecular pathogenesis and genomic changes |
| Q36717910 | Myelodysplastic syndromes: the complexity of stem-cell diseases |
| Q33947406 | NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia. |
| Q37949547 | PRDM proteins: important players in differentiation and disease |
| Q37455180 | Pathogenetic significance of ecotropic viral integration site-1 in hematological malignancies |
| Q21133010 | Phosphorylation of the leukemic oncoprotein EVI1 on serine 196 modulates DNA binding, transcriptional repression and transforming ability |
| Q39129759 | Point mutations in two EVI1 Zn fingers abolish EVI1-GATA1 interaction and allow erythroid differentiation of murine bone marrow cells. |
| Q36187534 | Predicting preferential DNA vector insertion sites: implications for functional genomics and gene therapy |
| Q37954583 | Prognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics |
| Q45168760 | Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes |
| Q35848227 | Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells |
| Q38686515 | Review: Aberrant EVI1 expression in acute myeloid leukaemia |
| Q26859843 | Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome research |
| Q30351255 | Runx1/AML1 in normal and abnormal hematopoiesis. |
| Q24685799 | SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice |
| Q39305389 | Selection for Evi1 activation in myelomonocytic leukemia induced by hyperactive signaling through wild-type NRas |
| Q43152261 | Significant increase of self-renewal in hematopoietic cells after forced expression of EVI1. |
| Q36900663 | Sites of retroviral DNA integration: From basic research to clinical applications |
| Q35237399 | Sox17 expression confers self-renewal potential and fetal stem cell characteristics upon adult hematopoietic progenitors |
| Q35849315 | Sox4 cooperates with Evi1 in AKXD-23 myeloid tumors via transactivation of proviral LTR. |
| Q41843904 | Stably integrated and expressed retroviral sequences can influence nuclear location and chromatin condensation of the integration locus |
| Q38171230 | Stem cell origin of myelodysplastic syndromes |
| Q34644740 | Survivin modulates genes with divergent molecular functions and regulates proliferation of hematopoietic stem cells through Evi-1 |
| Q28266315 | The MDS1-EVI1 gene complex as a retrovirus integration site: impact on behavior of hematopoietic cells and implications for gene therapy |
| Q36415991 | The genetics of the myelodysplastic syndromes: classical cytogenetics and recent molecular insights |
| Q38615755 | The microenvironment in myelodysplastic syndromes: niche-mediated disease initiation and progression. |
| Q41930387 | The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid |
| Q59790119 | The orphan nuclear receptor EAR-2 (NR2F6) inhibits hematopoietic cell differentiation and induces myeloid dysplasia in vivo |
| Q50723216 | Transcriptional regulatory network analysis of developing human erythroid progenitors reveals patterns of coregulation and potential transcriptional regulators. |
| Q37671806 | Unraveling the molecular pathophysiology of myelodysplastic syndromes |
| Q37407161 | Update on genetic and molecular markers associated with myelodysplastic syndromes. |
Search more.